Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 73
Filter
2.
Cutis ; 112(6): 262-263, 2023 Dec.
Article in English | MEDLINE | ID: mdl-38290066
3.
JAMA Dermatol ; 157(6): 716-720, 2021 06 01.
Article in English | MEDLINE | ID: mdl-33978670

ABSTRACT

Importance: In response to the coronavirus disease 2019 (COVID-19) pandemic, 2 mRNA vaccines (Pfizer-BioNTech and Moderna) received emergency use authorization from the US Food and Drug Administration in December 2020. Some patients in the US have developed delayed localized cutaneous vaccine reactions that have been dubbed "COVID arm." Objective: To describe the course of localized cutaneous injection-site reactions to the Moderna COVID-19 vaccine, subsequent reactions to the second vaccine dose, and to characterize the findings of histopathologic examination of the reaction. Design, Setting, and Participants: This retrospective case series study was performed at Yale New Haven Hospital, a tertiary medical center in New Haven, Connecticut, with 16 patients referred with localized cutaneous injection-site reactions from January 20 through February 12, 2021. Main Outcomes and Measures: We collected each patient's demographic information, a brief relevant medical history, clinical course, and treatment (if any); and considered the findings of a histopathologic examination of 1 skin biopsy specimen. Results: Of 16 patients (median [range] age, 38 [25-89] years; 13 [81%] women), 14 patients self-identified as White and 2 as Asian. The delayed localized cutaneous reactions developed in a median (range) of 7 (2-12) days after receiving the Moderna COVID-19 vaccine. These reactions occurred at or near the injection site and were described as pruritic, painful, and edematous pink plaques. None of the participants had received the Pfizer-BioNTech vaccine. Results of a skin biopsy specimen demonstrated a mild predominantly perivascular mixed infiltrate with lymphocytes and eosinophils, consistent with a dermal hypersensitivity reaction. Of participants who had a reaction to first vaccine dose (15 of 16 patients), most (11 patients) developed a similar localized injection-site reaction to the second vaccine dose; most (10 patients) also developed the second reaction sooner as compared with the first-dose reaction. Conclusions and Relevance: Clinical and histopathologic findings of this case series study indicate that the localized injection-site reactions to the Moderna COVID-19 vaccine are a delayed hypersensitivity reaction. These reactions may occur sooner after the second dose, but they are self-limited and not associated with serious vaccine adverse effects. In contrast to immediate hypersensitivity reactions (eg, anaphylaxis, urticaria), these delayed reactions (dubbed "COVID arm") are not a contraindication to subsequent vaccination.


Subject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Drug Eruptions/epidemiology , Injection Site Reaction/epidemiology , 2019-nCoV Vaccine mRNA-1273 , Adult , Aged , Aged, 80 and over , Connecticut/epidemiology , Drug Eruptions/diagnosis , Drug Eruptions/drug therapy , Drug Eruptions/immunology , Female , Histamine Antagonists/therapeutic use , Humans , Injection Site Reaction/diagnosis , Injection Site Reaction/drug therapy , Injection Site Reaction/immunology , Male , Middle Aged , Retrospective Studies , Skin/immunology , Skin/pathology
4.
J Am Acad Dermatol ; 85(5): 1218-1226, 2021 11.
Article in English | MEDLINE | ID: mdl-32387633

ABSTRACT

BACKGROUND: Patch testing is the best diagnostic test for allergic contact dermatitis. However, there is presently a lack of data on the test's geographic availability and the characteristics of the providers offering this test across the United States. OBJECTIVE: To evaluate the geographic variation in the availability of patch testing for the Medicare population and to characterize the temporal trends of patch testing cost, use, and provider specialty from 2012 to 2017. METHODS: Retrospective cohort study of the Medicare Provider Utilization and Payment Data from 2012 to 2017. RESULTS: As of 2017, patch testing was available in 20.3% of metropolitan counties and in 1.1% of nonmetropolitan counties. From 2012 to 2017 in metropolitan regions, the number of beneficiaries tested by dermatologists grew by an average annual growth rate of 1.84%, whereas those tested by allergists grew by an average annual growth rate of 20.31%. Most providers that averaged use of 80 or more patches per beneficiary were dermatologists (76.3%). LIMITATIONS: Analysis was restricted to Medicare Part B claims; data were unavailable on individuals with commercial insurance. CONCLUSIONS: Most of the increase in patch testing utilization from 2012 to 2017 has been in metropolitan regions. Although growth was especially prominent among allergists in metropolitan counties, the majority of providers performing comprehensive patch testing were dermatologists.


Subject(s)
Medicare , Aged , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/epidemiology , Humans , Medicine , Patch Tests , Retrospective Studies , United States
6.
J Am Acad Dermatol ; 83(6): 1730-1737, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32707253

ABSTRACT

The recent COVID-19 pandemic has resulted in increased hand hygiene and hand cleansing awareness. To prevent virus transmission, the Centers for Disease Control and Prevention recommends frequent hand washing with soap and water. Hand hygiene products are available in a variety of forms, and while each of these formulations may be effective against COVID-19, they may also alter skin barrier integrity and function. As health care workers and the general population focus on stringent hand hygiene, the American Contact Dermatitis Society anticipates an increase in both irritant contact and allergic contact hand dermatitis. Alcohol-based hand sanitizers with moisturizers have the least sensitizing and irritancy potential when compared to soaps and synthetic detergents. This article provides an overview of the most frequently used hand hygiene products and their associations with contact dermatitis as well as recommendations from the American Contact Dermatitis Society on how to treat and prevent further dermatitis.


Subject(s)
Dermatitis, Contact/prevention & control , Dermatitis, Occupational/prevention & control , Hand Dermatoses/prevention & control , Hand Hygiene/standards , Practice Guidelines as Topic , Anti-Infective Agents, Local/administration & dosage , Anti-Infective Agents, Local/adverse effects , Betacoronavirus/pathogenicity , COVID-19 , Communicable Disease Control/methods , Communicable Disease Control/standards , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Coronavirus Infections/transmission , Coronavirus Infections/virology , Dermatitis, Contact/etiology , Dermatitis, Occupational/etiology , Hand Dermatoses/chemically induced , Health Personnel , Humans , Irritants/administration & dosage , Irritants/adverse effects , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/transmission , Pneumonia, Viral/virology , SARS-CoV-2 , Soaps/adverse effects , Societies, Medical/standards , United States
7.
Dermatitis ; 31(2): 112-121, 2020.
Article in English | MEDLINE | ID: mdl-32168142

ABSTRACT

BACKGROUND: The American Contact Dermatitis Society Contact Allergen Management Program (CAMP) database was developed to provide patients with safe alternative products free of selected contact allergens. However, the CAMP database also records valuable information including the frequency of contact allergen searches for patients. OBJECTIVES: The aim of the study was to determine the relative prevalence of contact allergens in North America. METHODS: Data from the CAMP database were analyzed from January 1, 2018, to January 1, 2019. The number of searches performed for each specific allergen served as a measure of the relative prevalence for each contact allergen. Results were then stratified by age, sex, atopic history, and patch screening tray used. RESULTS: The 2018 CAMP data show that many of the prevalent allergens are not currently on any contact allergy screening series. These data strongly indicate that testing only to an 80-item screening series will not provide adequate care for many patients with contact allergy. The most prevalent contact allergens seen were fragrance mix, nickel, balsam of Peru, methylchloroisothiazolinone/methylisothiazolinone, and cobalt. Some important differences are seen when stratifying CAMP data by age, sex, atopic history, and patch screening tray used. LIMITATIONS: Possible sources of data error exist because of lack of uniformity of patch test practices. CONCLUSIONS: The CAMP database can be used to determine the relative prevalence of contact allergens, to help develop North American core screening patch test series, and to document the medical necessity of more comprehensive patch testing for patients with recalcitrant contact allergy.


Subject(s)
Allergens/adverse effects , Dermatitis, Allergic Contact/epidemiology , Dermatitis, Allergic Contact/etiology , Adolescent , Adult , Balsams/adverse effects , Child , Child, Preschool , Cobalt/adverse effects , Databases, Factual , Dermatitis, Allergic Contact/diagnosis , Humans , Infant , Infant, Newborn , Nickel/adverse effects , North America/epidemiology , Odorants , Patch Tests , Perfume/adverse effects , Prevalence , Thiazoles/adverse effects , Young Adult
8.
Dermatitis ; 27(5): 241-7, 2016.
Article in English | MEDLINE | ID: mdl-27649347

ABSTRACT

The American Contact Dermatitis Society recognizes the interest in the evaluation and management of metal hypersensitivity reactions. Given the paucity of robust evidence with which to guide our practices, we provide reasonable evidence and expert opinion-based guidelines for clinicians with regard to metal hypersensitivity reaction testing and patient management. Routine preoperative evaluation in individuals with no history of adverse cutaneous reactions to metals or history of previous implant-related adverse events is not necessary. Patients with a clear self-reported history of metal reactions should be evaluated by patch testing before device implant. Patch testing is only 1 element in the assessment of causation in those with postimplantation morbidity. Metal exposure from the implanted device can cause sensitization, but a positive metal test does not prove symptom causality. The decision to replace an implanted device must include an assessment of all clinical factors and a thorough risk-benefit analysis by the treating physician(s) and patient.


Subject(s)
Dermatitis, Allergic Contact/diagnosis , Metals , Patch Tests , Prostheses and Implants , Humans , Societies, Medical
9.
Dermatitis ; 27(4): 186-92, 2016.
Article in English | MEDLINE | ID: mdl-27427820

ABSTRACT

Allergic contact dermatitis (ACD) may complicate the clinical course of atopic dermatitis (AD), and patch testing remains the criterion standard for diagnosing ACD. To date, there have been no guidelines or consensus recommendations on when and how to patch test individuals with AD. Failure to patch test when appropriate may result in overlooking an important and potentially curable complicating comorbidity. In this article, we present consensus recommendations regarding when to perform patch testing in the AD patient, best practices, and common pitfalls. Patch testing should be considered in AD patients with dermatitis that fails to improve with topical therapy; with atypical/changing distribution of dermatitis, or pattern suggestive of ACD; with therapy-resistant hand eczema in the working population; with adult- or adolescent-onset AD; and/or before initiating systemic immunosuppressants for the treatment of dermatitis. A suggested patch testing algorithm for AD patients is provided.


Subject(s)
Dermatitis, Allergic Contact/diagnosis , Dermatitis, Atopic/epidemiology , Patch Tests/methods , Comorbidity , Consensus , Dermatitis, Allergic Contact/epidemiology , Dermatitis, Allergic Contact/etiology , Humans
11.
Clin Pharmacol Ther ; 99(2): 172-85, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26479518

ABSTRACT

This article provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using different nomenclature systems. In addition, PGx analysis may detect different sets of variants for each gene, which can affect interpretation of results. This practice has caused confusion and may thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx forward.


Subject(s)
Alleles , Genetic Testing/standards , Pharmacogenetics/standards , Terminology as Topic , Genes , Genetic Testing/trends , Genetic Variation , Humans , Pharmacogenetics/trends , Precision Medicine
12.
Immunol Invest ; 44(7): 665-77, 2015.
Article in English | MEDLINE | ID: mdl-26436852

ABSTRACT

Interleukin-21 (IL-21) upregulation was observed in Crohn's disease (CD) patients and was shown to contribute to ongoing mucosal inflammation in CD patients through stabilizing Th1 cell differentiation and IFN-γ production. Given the role of IL-21 in mediating adaptive B cell antibody responses in healthy individuals, we examined the effect of IL-21 upregulation in B cell responses in patients with active CD, including ileum, ileocolonic and colon subtypes, defined by the primary site of CD involvement. We first observed an upregulation of blood plasma IL-21 concentration and IL-21 production from CD4(+) T cells in CD patients compared to healthy individuals. The IL-21-expressing T cells were more concentrated in the CD4(+)CXCR5(+) compartment, both in unstimulated medium and after stimulation with SEB. ICOS and PD-1 expressions were also concentrated in the CD4(+)CXCR5(+) subset in CD patients. Since peripheral blood CD4(+)CXCR5(+) T cell-mediated antibody secretion is IL-21-dependent, we examined the plasma antibody concentration in CD patients and healthy controls. We found that CD patients had significantly higher plasma Ig level than healthy patients, with no significant differences between different CD subtypes. Higher plasma IL-21 concentration and increased IL-21 production from CD4(+) T cells were directly correlated with higher plasma antibody levels. Moreover, we found that IL-21 and CD4(+)CXCR5(+) T cells can directly enhance B cell antibody response in CD patients. Depletion of secreted IL-21 by sIL-21R addition compromised the CD4(+)CXCR5(+) T cell-mediated increase in antibody production. Together, our results demonstrated a novel role of IL-21 in mediating B cell inflammation in CD development.


Subject(s)
Antibody Formation/immunology , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Crohn Disease/immunology , Crohn Disease/metabolism , Interleukins/metabolism , Adult , CD4 Lymphocyte Count , Case-Control Studies , Crohn Disease/blood , Crohn Disease/diagnosis , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunophenotyping , Interleukins/blood , Male , Middle Aged , Receptors, CXCR5/metabolism , Severity of Illness Index , Young Adult
14.
Chem Commun (Camb) ; 51(65): 12981-4, 2015 Aug 21.
Article in English | MEDLINE | ID: mdl-26176021

ABSTRACT

Azonium ions formed by p-amino substituted azo compounds with both ortho- and meta-methoxy substituents exhibit strong absorbance in far-red and near infrared spectral region. The compounds undergo robust photoswitching in aqueous solution and exhibit a range of thermal relaxation rates from 10 µs-100 ms.


Subject(s)
Azo Compounds/chemistry , Infrared Rays , Ions/chemistry , Isomerism , Light , Photochemical Processes
15.
J Cutan Pathol ; 42(10): 757-64, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25989266

ABSTRACT

A 37-year-old pregnant woman presented with a 2-cm irregular reddish nodule on her left upper arm during pregnancy. A biopsy from the lesion showed a 2.2-mm thick malignant melanoma with intravascular invasion, 25 mitosis/mm(2) and no ulceration. Following induction of labor, the patient underwent re-excision with sentinel lymph node biopsy. This showed no residual melanoma and no lymph node metastasis. The newborn boy had multiple pigmented lesions on the trunk, some of which were large and irregular. Two were biopsied and histologic examination showed dense dermal proliferation of medium sized melanocytes with multiple mitotic figures and no maturation with their descent into the dermis, raising suspicion of transplacental metastases. Examination of the placenta failed to show metastatic lesions. Multiplex polymerase chain reaction (PCR)-based genotyping, including testing for amelogenin locus for sex chromosome determination, demonstrated the presence of Y chromosome material in the melanocytes of the newborn's lesions excluding maternal origin. A diagnosis of congenital nevi was rendered. Subsequently, Imaging Mass Spectrometric analysis of the mother's lesion showed proteomic signature expression indicative of malignant melanoma, whereas the two lesions in the newborn showed changes indicative of nevi. This case demonstrates the utility of genotyping and Mass Spectrometry analysis in this challenging clinical scenario.


Subject(s)
Melanoma/congenital , Nevus, Pigmented/congenital , Pregnancy Complications, Neoplastic/pathology , Sex Chromosomes , Skin Neoplasms/pathology , Adult , Female , Follow-Up Studies , Humans , Infant, Newborn , Male , Mass Spectrometry/methods , Melanoma/genetics , Melanoma/pathology , Neoplasm Metastasis , Nevus, Pigmented/genetics , Nevus, Pigmented/pathology , Placenta/pathology , Pregnancy , Sentinel Lymph Node Biopsy , Skin Neoplasms/genetics , Melanoma, Cutaneous Malignant
16.
Pediatr Dermatol ; 32(4): e161-2, 2015.
Article in English | MEDLINE | ID: mdl-25782705

ABSTRACT

A 17-year-old boy presented with recurring severe dermatitis of the face of 5-months duration that resembled impetigo. He had been treated with several courses of antibiotics without improvement. Biopsy showed changes consistent with allergic contact dermatitis and patch testing later revealed sensitization to benzoyl peroxide, which the patient had been using for the treatment of acne vulgaris.


Subject(s)
Benzoyl Peroxide/adverse effects , Dermatitis, Allergic Contact/etiology , Dermatologic Agents/adverse effects , Impetigo/diagnosis , Skin/pathology , Acne Vulgaris/drug therapy , Adolescent , Biopsy , Dermatitis, Allergic Contact/pathology , Diagnosis, Differential , Humans , Male , Recurrence
19.
Orv Hetil ; 155(24): 939-48, 2014 Jun 15.
Article in Hungarian | MEDLINE | ID: mdl-24918176

ABSTRACT

Stress is considered as a major contributor to the development and exacerbation of psoriasis by a significant proportion of patients and dermatologists. As both stressor and its effects are subject-dependent, thus extremely difficult to measure, our understanding of the exact role of stress in disease development was limited for a long time. In the past decade several new studies were carried out which expanded our knowledge on the pathophysiologic processes linking stress to psoriasis via with their objective measurements and the applied new techniques. The authors review the current literature of both psychological (alexithymia, personality, affect) and biological (cortisol, epinephrine, neurogenic inflammation) factors influencing stress perception and response in psoriasis. Results of recent investigations support previous reports about the interaction between stress and psoriasis with objective evidence. Knowing how effective stress-reducing psychopharmacologic and psychotherapeutic interventions are in the treatment of psoriasis the authors hope that this review contributes to a wider acceptance of the psychosomatic attitude in everyday dermatologic practice.


Subject(s)
Psoriasis/prevention & control , Psoriasis/psychology , Stress, Psychological/complications , Stress, Psychological/therapy , Humans , Hydrocortisone/blood , Hypothalamo-Hypophyseal System/metabolism , Pituitary-Adrenal System/metabolism , Psoriasis/metabolism , Psoriasis/physiopathology , Recurrence , Secondary Prevention/methods , Stress, Psychological/metabolism , Stress, Psychological/physiopathology , Stress, Psychological/prevention & control
20.
Biochemistry ; 50(23): 5249-62, 2011 Jun 14.
Article in English | MEDLINE | ID: mdl-21561160

ABSTRACT

Light-induced hypsochromic shifts of the Q(y) absorption band of the bacteriochlorophyll dimer (P) from 865 to 850 nm were identified using continuous illumination of dark-adapted reaction centers (RCs) from Rhodobacter capsulatus when dispersed in the most commonly used detergent, the zwitterionic lauryl N-dimethylamine-N-oxide. Such a shift is known to be the consequence of the decreased degree of delocalization of P. A 2-fold acceleration of the recovery kinetics of P(+) was found in RCs that underwent light-induced structural changes compared to those where the P-band position did not change. The light-induced shift was irreversible except in the presence of a secondary electron donor. Prolonged (15 min) illumination resulted in a shift in the position of the P-band even in neutral or negatively charged detergents. In contrast, RCs reconstituted into liposomes made from lipids with different headgroup charges showed light-induced shifts only if shorter fatty acid chains were used. The light-induced conformational changes caused a prominent decrease of the redox potential of P ranging from 120 to 160 mV depending on the detergent compared to the potential of P in dark-adapted reaction centers. The measured light-induced potential decreases were 55 to 85 mV larger than those reported for reaction centers where the P-band position remained at 865 nm. The influence of structural factors, such as the delocalization of the electron hole on P(+), the involvement of Tyr M210, and the hydrophobic mismatch between the thickness of the hydrophobic belt of the detergent micelles or the lipid bilayer and the RC protein, on the spectral features and electron transfer kinetics is discussed.


Subject(s)
Detergents/chemistry , Lipid Bilayers/chemistry , Photosynthetic Reaction Center Complex Proteins/chemistry , Rhodobacter sphaeroides/metabolism , Electron Transport , Kinetics , Liposomes , Micelles , Models, Molecular , Oxidation-Reduction , Photosynthetic Reaction Center Complex Proteins/metabolism , Photosynthetic Reaction Center Complex Proteins/radiation effects , Protein Conformation , Tyrosine/chemistry , Tyrosine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL